Resources - Webinars

New, Automated Non-Radioactive Assay Technologies for Use in Antibody-Dependent Cell-Mediated Cytotoxicity Applications

Related Products: Precision, Synergy H1, Synergy Neo2

November 16, 2012

Presenter: Brad Larson, Principal Scientist at BioTek Instruments, Inc.

With many of the existing patents covering antibody-based therapeutics set to expire in the next few years, the development of biologic therapeutics similar to the original drug (biosimilars) has become increasingly important. As a direct result, assays that can assess the ability of a biosimilar to act in a manner similar to the original biologic have also seen increased interest. One of the mechanisms which plays a central role in the response to clinical antibody therapy is antibody-dependent cell-mediated cytotoxicity (ADCC). The current “gold standard” ADCC assay incorporates 51Cr. Newer non-radioactive ADCC assays, however, have recently been developed, which are easier to use and more amenable to automation, while still delivering accurate results. An overview of these technologies will be presented during this webinar, with an emphasis on how each procedure can be efficiently automated in 96- or 384-well format using freshly isolated or cryopreserved Natural Killer (NK) cells, NK cell lines, or other relevant genetically modified cell lines.

New, Automated Non-Radioactive Assay Technologies for Use in Antibody-Dependent Cell-Mediated Cytotoxicity Applications

link